Psycheceutical utilizes its patented NeuroDirect™ non-systemic delivery technology to administer psychedelic pharmaceutical medicines directly into nerve tissue via topical application, bypassing the gastrointestinal tract. This method enhances dosage control and minimizes side effects, addressing the need for safer and more effective treatments for neuropsychiatric and pain conditions.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods of administering psychedelic medicines often involve systemic delivery, leading to unpredictable absorption, significant side effects, and the need for clinical settings, increasing costs and limiting patient access. Existing oral or intravenous routes can result in variable drug concentrations and unwanted psychoactive effects.
Solution
Psycheceutical Bioscience is developing a non-systemic drug delivery platform, NeuroDirect™, designed to administer psychedelic compounds directly into nerve tissue via topical application. This targeted approach bypasses the gastrointestinal tract and reduces systemic exposure, potentially minimizing side effects such as hallucinations, nausea, and dizziness. By delivering medication directly to the nervous system, NeuroDirect™ aims to provide more consistent and controlled therapeutic outcomes. The technology is being developed for at-home administration, which could significantly lower treatment costs and improve accessibility for patients suffering from mental health and neurodegenerative disorders.
Target Audience
The primary target audience includes individuals suffering from neuropsychiatric and neurodegenerative conditions, as well as healthcare providers seeking safer, more effective, and accessible methods for administering psychedelic medicines.
Features
- Patented NeuroDirect™ technology for topical, non-systemic delivery of neuro-active compounds
- Targeted drug administration directly to nerve tissue at the back of the neck
- Designed to minimize systemic side effects and enhance dosage control
- Potential for at-home administration, reducing the need for clinical supervision
- Formulation designed for immediate and sustained drug delivery
- Currently in Phase I clinical trials for topical ketamine treatment of PTSD